Elezanumab (ABT-555) is a monoclonal antibody RGMa inhibitor being investigated to treat spinal cord injuries and multiple sclerosis.

Type of Molecule

Biologic

Target

RGMa

Region

n/a

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Multiple Sclerosis (MS) New Indication Phase 1
Spinal Cord Injury New Indication Phase 1